Ali Khademhosseini

Ali Khademhosseini (, born October 30, 1975) is an Iranian-born Canadian-American engineer and entrepreneur.

Khademhosseini was the CEO of the Terasaki Institute for Biomedical Innovation (TIBI) in Los Angeles, California. Before that he held a multi-departmental professorship at the University of California, Los Angeles (UCLA), where he served as the Levi Knight Chair in Engineering and a professor in the departments of Bioengineering, Radiology, and Chemical and Biomolecular Engineering. He also served as the director of the Center for Minimally Invasive Therapeutics (C-MIT) at UCLA. He was principal scientist at Amazon during his transition between UCLA to TIBI.

Prior to joining UCLA, he was a faculty member at Harvard Medical School and a core faculty member at the Wyss Institute for Biologically Inspired Engineering from 2005 to 2017. In addition to his academic roles, Khademhosseini briefly worked at Amazon Inc., contributing to biomedical technology initiatives during a one-year tenure.

Khademhosseini has published approximately 1,000 scientific articles, which have collectively been cited over 157,000 times. As of January 2026, his h-index is 205. His work spans biomaterials, tissue engineering, microfluidics, and biofabrication, with key contributions to the development of Gelatin Methacryloyl (GelMA) hydrogels and multi-organ-on-a-chip platforms.

In addition to his academic career, Khademhosseini is also active in technology translation and entrepreneurship. He has contributed to the development of commercial products in the biomedical space, including surgical sealants, wearable sensors, and embolic materials. Provided by Wikipedia